anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
slides · global inventory

Title

Component collection for the active corpus filters, with each row opening the slide detail view.

Search Insights JSON Unlock
Matching slides 303,780
Current window 226,501-226,530
Pages 10,126
Rows per page 30
Component: Titleclear collectionreset all
18 30 60

Component

226,501-226,530 of 303,780

filter-aware
34
The chart demonstrates deepening clinical responses over time for NXC-201 therapy.Immix Biopharma | Investor Presentation Deck | 60 slides · Immix Biopharma
Pitch deck Investor relations Beat · TractionLoop · Golden Circle1 hit
35
Includes a complex biological pathway diagram and three supporting charts demonstrating efficacy.Immix Biopharma | Investor Presentation Deck | 60 slides · Immix Biopharma
Pitch deck Investor relations Loop · Golden Circle1 hit
36
The slide uses a numbered list format to present key value propositions.Immix Biopharma | Investor Presentation Deck | 60 slides · Immix Biopharma
Pitch deck Investor relations Loop · Golden Circle1 hit
37
Immix Biopharma | Investor Presentation Deck | 60 slidesImmix Biopharma | Investor Presentation Deck | 60 slides · Immix Biopharma
Pitch deck Investor relations Loop · Golden Circle1 hit
39
The table compares CRS and ICANS incidence and management across three dosage groups (150x10^6, 450x10^6, and 800x10^6 cells).Immix Biopharma | Investor Presentation Deck | 60 slides · Immix Biopharma
Pitch deck Investor relations Loop · Golden Circle1 hit
40
The slide highlights specific toxicity data (CRS and ICANS) for a competitor product.Immix Biopharma | Investor Presentation Deck | 60 slides · Immix Biopharma
Pitch deck Investor relations Loop · Golden Circle1 hit
41
Highlights NXC-201's lower fludarabine dose and Carvykti's longer infusion window.Immix Biopharma | Investor Presentation Deck | 60 slides · Immix Biopharma
Pitch deck Investor relations Loop · Golden Circle1 hit
42
The table compares four different therapies across four criteria categories: Prior lines of therapy, Toxicity recovery, ECOG, and Measurable disease.Immix Biopharma | Investor Presentation Deck | 60 slides · Immix Biopharma
Pitch deck Investor relations Loop · Golden Circle1 hit
43
The slide highlights a competitive advantage for NXC-201 regarding patient eligibility.Immix Biopharma | Investor Presentation Deck | 60 slides · Immix Biopharma
Pitch deck Investor relations Loop · Golden Circle1 hit
44
The slide uses a bar chart to compare two groups of drugs and their associated companies.Immix Biopharma | Investor Presentation Deck | 60 slides · Immix Biopharma
Pitch deck Investor relations Loop · Golden Circle1 hit
45
Slide presents three distinct preclinical data sets: survival in STS mice, tumor response in STS mice, and survival in KPC pancreatic cancer mice.Immix Biopharma | Investor Presentation Deck | 60 slides · Immix Biopharma
Pitch deck Investor relations Loop · Golden Circle1 hit
46
Includes a process flow diagram illustrating the mechanism of action of IMX-110 in tumor microenvironments.Immix Biopharma | Investor Presentation Deck | 60 slides · Immix Biopharma
Pitch deck Investor relations Loop · Golden Circle1 hit
47
Includes Kaplan-Meier survival curves and bioluminescence imaging of tumor activity.Immix Biopharma | Investor Presentation Deck | 60 slides · Immix Biopharma
Pitch deck Investor relations Loop · Golden Circle1 hit
48
Includes waterfall and spider/line plots for patient response data.Immix Biopharma | Investor Presentation Deck | 60 slides · Immix Biopharma
Pitch deck Investor relations Loop · Golden Circle1 hit
49
The slide uses a bubble chart to map clinical trials and a table to detail drug performance metrics.Immix Biopharma | Investor Presentation Deck | 60 slides · Immix Biopharma
Pitch deck Investor relations Loop · Golden Circle1 hit
50
The slide uses a combination of a conceptual chart and a data table to demonstrate efficacy in heavily pre-treated patients.Immix Biopharma | Investor Presentation Deck | 60 slides · Immix Biopharma
Pitch deck Investor relations Loop · Golden Circle1 hit
51
The slide uses a process flow diagram to illustrate the clinical development path for two different treatment regimens.Immix Biopharma | Investor Presentation Deck | 60 slides · Immix Biopharma
Pitch deck Investor relations Loop · Golden Circle1 hit
52
Includes a comparative diagram of the drug molecule vs standard IgG antibody and multiple clinical/preclinical data charts.Immix Biopharma | Investor Presentation Deck | 60 slides · Immix Biopharma
Pitch deck Investor relations Loop · Golden Circle1 hit
53
Includes two sets of charts: tumor volume line graphs and survival curves for MDA-MB-231 and HCT-116 models.Immix Biopharma | Investor Presentation Deck | 60 slides · Immix Biopharma
Pitch deck Investor relations Loop · Golden Circle1 hit
54
Includes detailed scientific diagrams of the drug mechanism and clinical trial results.Immix Biopharma | Investor Presentation Deck | 60 slides · Immix Biopharma
Pitch deck Investor relations Loop · Golden Circle1 hit
55
The slide uses a bar chart comparison to highlight the efficacy gap between established treatments and placebo.Immix Biopharma | Investor Presentation Deck | 60 slides · Immix Biopharma
Pitch deck Investor relations Loop · Golden Circle1 hit
56
The slide uses a side-by-side comparison of two proprietary technology platforms.Immix Biopharma | Investor Presentation Deck | 60 slides · Immix Biopharma
Pitch deck Investor relations Loop · Golden Circle1 hit
58
The slide uses a serpentine process flow (1-5 left-to-right, 6-10 right-to-left).Immix Biopharma | Investor Presentation Deck | 60 slides · Immix Biopharma
Pitch deck Investor relations Loop · Golden Circle1 hit
01
Slide 1
Immix Biopharma | Investor Presentation Deck | 61 slidesImmix Biopharma | Investor Presentation Deck | 61 slides · Immix Biopharma
Pitch deck Investor relations Beat · Attention1 hit
02
Immix Biopharma | Investor Presentation Deck | 61 slidesImmix Biopharma | Investor Presentation Deck | 61 slides · Immix Biopharma
Pitch deck Investor relations Beat · Attention1 hit
03
The slide uses a numbered list format to present key value propositions.Immix Biopharma | Investor Presentation Deck | 61 slides · Immix Biopharma
Pitch deck Investor relations Beat · Attention1 hit
04
The slide uses a grid-based layout to categorize team members into three distinct groups: Leadership, Board of Directors, and Scientific Advisory Board.Immix Biopharma | Investor Presentation Deck | 61 slides · Immix Biopharma
Pitch deck Investor relations Beat · Interest1 hit
05
The slide uses a causal-chain framework to link platform capabilities to strategic outcomes.Immix Biopharma | Investor Presentation Deck | 61 slides · Immix Biopharma
Pitch deck Investor relations Beat · Interest1 hit
06
Uses a hub-and-spoke diagram to illustrate the negative impacts of a central problem.Immix Biopharma | Investor Presentation Deck | 61 slides · Immix Biopharma
Pitch deck Investor relations Beat · InterestLoop · Logic Chain1 hit
08
The slide uses a schematic diagram to map specific protein domains to their functional benefits.Immix Biopharma | Investor Presentation Deck | 61 slides · Immix Biopharma
Pitch deck Investor relations Beat · InterestLoop · Logic Chain1 hit